Emergex

Emergex Vaccines is a UK-based clinical-stage biotechnology company developing a new class of synthetic peptide vaccines designed to stimulate cytotoxic T-lymphocyte (CTL) responses rather than the antibody-driven immunity targeted by conventional vaccines. Founded in 2015 and headquartered in Abingdon, Oxfordshire, the company was established on the premise that T-cell immunity offers broader and more durable protection against rapidly mutating viral pathogens, including pandemic influenza strains and other emerging infectious threats.

Platform Technology and Pipeline

The company's core platform centres on short synthetic peptide constructs derived from conserved viral protein sequences. Because these sequences change little across viral variants, the approach aims to produce vaccines with cross-strain efficacy, addressing a central limitation of seasonal influenza vaccines that must be reformulated annually. Emergex has advanced candidates targeting influenza A and dengue fever through early-phase clinical evaluation, with additional programmes directed at other flaviviruses and respiratory viruses.

Development and Funding Background

Emergex has received support from UK public funding bodies and private investors to progress its pipeline from pre-clinical research into Phase I clinical trials. The company operates under a largely asset-light model, collaborating with contract research organisations and academic partners to conduct clinical work. As a private company, Emergex does not carry a public stock listing. Its programmes are positioned within the broader landscape of next-generation vaccine development, addressing unmet needs in both seasonal infectious disease management and pandemic preparedness.

Further information is available at emergexvaccines.com.